TRANSGENE (EPA:TNG) | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
TRANSGENE

BRIEF

published on 09/13/2024 at 10:37, 2 months 8 days ago

Franchissement de seuil par SITAM Belgique dans TRANSGENE S.A.

Droits De Vote Franchissement De Seuil Augmentation De Capital SITAM Belgique TRANSGENE S.A.
PRESS RELEASE

published on 09/13/2024 at 10:32, 2 months 8 days ago

Franchissement de seuil
Déclaration de franchissement de seuil de la société TRANSGENE S.A. par SITAM Belgique, détenant 3,65% du capital et 4,85% des droits de vote

Déclaration Franchissement De Seuil AMF SITAM Belgique TRANSGENE S.A.
BRIEF

published on 09/10/2024 at 07:35, 2 months 11 days ago

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

Cancer Treatment Oncology Leadership Immunotherapy Transgene
BRIEF

published on 09/10/2024 at 07:35, 2 months 11 days ago

Transgene nomme deux leaders chevronnés en oncologie pour piloter sa prochaine phase d'innovation

Immunothérapie Direction Oncologie Traitement Du Cancer Transgene
PRESS RELEASE

published on 09/10/2024 at 07:30, 2 months 11 days ago

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Transgene appoints Dr. Emmanuelle Dochy as CMO and Dr. Maurizio Ceppi as CSO to drive innovation in cancer immunotherapies. Company progresses clinical pipeline with therapeutic vaccine TG4050

Innovation Oncology Clinical Pipeline Immunotherapy Transgene
BRIEF

published on 08/27/2024 at 07:35, 2 months 25 days ago

Transgene publie des données précliniques sur le virus oncolytique TG6050 au JITC

Transgene Données Précliniques TG6050 JITC Virus Oncolytique
BRIEF

published on 08/27/2024 at 07:35, 2 months 25 days ago

Transgene Publishes Preclinical Data on Oncolytic Virus TG6050 in JITC

Preclinical Data Transgene Oncolytic Virus TG6050 JITC
PRESS RELEASE

published on 08/27/2024 at 07:30, 2 months 25 days ago

Transgene publie dans le JITC des données de preuve de concept préclinique du virus oncolytique TG6050
Transgene publie des données précliniques démontrant l'efficacité de TG6050, virus oncolytique pour le cancer du poumon. Études prometteuses pour le développement clinique

Transgene Cancer Du Poumon Étude Préclinique TG6050 Virus Oncolytique
PRESS RELEASE

published on 08/27/2024 at 07:30, 2 months 25 days ago

Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC
Transgene announces preclinical proof-of-concept data of oncolytic virus TG6050 published in JITC, showcasing tumor regression and immune remodeling capabilities without systemic toxicity. TG6050 progressing in Phase I trial for NSCLC

Phase I Trial Transgene Oncolytic Virus TG6050 JITC Publication
BRIEF

published on 07/30/2024 at 21:06, 3 months 21 days ago

Transgene consolidates its balance sheet thanks to the conversion of part of the advance into shares

Biotechnology Immunotherapy Increase In Capital Transgene Mérieux Institute

Accesswire

Published on 11/21/2024 at 12:00, 48 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 48 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 18 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 45 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 48 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 13 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 33 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 42 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 48 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 18 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 50 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 50 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 50 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 41 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 28 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE